Denatonium Acetate Monohydrate Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Denatonium acetate anhydrous (DAA) is insufficiently stable and does not meet FDA regulatory requirements for stability, making it unsuitable as an active pharmaceutical ingredient for treating conditions like metabolic syndrome, obesity, and hyperglycemia.
Innovation Solution
Denatonium acetate monohydrate (DAM) is synthesized by hydrating and recrystallizing DAA, providing a more stable salt form characterized by improved physical and chemical stability, which can be prepared through a process involving contact with a lower alkyl isobutyl ketone and water, resulting in a crystalline monohydrate with enhanced stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If denatonium acetate anhydrous (DAA) is used as the active pharmaceutical ingredient, then the therapeutic effect for treating metabolic syndrome, obesity, and hyperglycemia is achieved, but the stability under stress conditions (high temperature, humidity) is insufficient and does not meet FDA regulatory requirements
Solution Approach 1:
The patent applies parameter changes by transforming the chemical composition parameters of denatonium acetate from anhydrous form to monohydrate form. This changes the molecular structure parameters (adding water of crystallization) which directly improves the stability parameters under stress conditions including high temperature and humidity, thereby resolving the contradiction between therapeutic effectiveness and chemical stability.
Solution Approach 2:
The patent creates a composite material structure by forming denatonium acetate monohydrate, which combines the active pharmaceutical ingredient with water molecules in a crystalline lattice. This composite structure provides enhanced stability under stress conditions while maintaining the therapeutic properties of the original compound, thus resolving the stability contradiction.
2Reliability
If denatonium acetate anhydrous (DAA) is synthesized and stored, then the active pharmaceutical ingredient is available for use, but degradation occurs under stress conditions leading to loss of therapeutic effectiveness
Solution Approach 1:
The patent changes the physical and chemical parameters of denatonium acetate by converting it from anhydrous to monohydrate form. This parameter change stabilizes the compound against degradation under stress conditions, thereby extending the shelf life and duration of storage while preserving therapeutic effectiveness.
Solution Approach 2:
The patent applies beforehand cushioning by pre-hydrating the denatonium acetate to form the monohydrate salt before storage. This pre-stabilization protects the compound from subsequent degradation during storage and transport under various stress conditions, thus extending shelf life and maintaining therapeutic effectiveness throughout the product lifecycle.
3Reliability
If a stable salt form of denatonium acetate is developed, then FDA regulatory requirements for stability are met, but additional processing steps (hydration and recrystallization) are required
Solution Approach 1:
The patent applies preliminary action by incorporating the hydration step into the synthesis process itself, rather than treating it as a separate post-synthesis operation. The synthesis methodology is designed to directly produce the stable monohydrate form, making the stability-enhancing transformation part of the primary manufacturing process rather than an additional step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The denatonium acetate monohydrate salt exhibits improved stability under stress conditions such as high temperatures and humidity, maintaining its crystalline form and therapeutic effectiveness, addressing the stability issues of DAA and enabling its use as a stable API.
Implementation Method 1
DAA was hydrated and recrystallized into a stable salt, i.e., denatonium acetate monohydrate (DAM)
Implementation Method 2
contacting an equivalent of DAA (denatonium acetate, anhydrous) with a lower alkyl isobutyl ketone, such as methyl isobutyl ketone, and water
Implementation Method 3
recovering the resultant solid phase, and removing the solid therefrom. The denatonium acetate monohydrate is a crystalline monohydrate
Data Source
AI summary
There is disclosed a novel monohydrate salt form of denatonium acetate. More particularly, the novel salt form and crystalline hydrate form is useful for the treatment and prevention of diseases and conditions, such as metabolic syndrome, obesity, NASH, glycemic control/diabetes, and IBD (intestinal bowel disease).